Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Januar 2026 12:49 ET | Quelle: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants...
21. Januar 2026 06:23 ET | Quelle: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)...
16. Januar 2026 13:30 ET | Quelle: Genmab A/S

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 –...
07. Januar 2026 09:00 ET | Quelle: Genmab A/S

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody...